09:23 AM EDT, 08/01/2024 (MT Newswires) -- Blueprint Medicines ( BPMC ) reported a Q2 net loss Thursday of $0.80 per diluted share, narrower than a loss of $2.19 a year earlier.

Analysts polled by Capital IQ expected a loss of $1.29.

Revenue for the quarter ended June 30 was $138.2 million, up from $57.6 million a year earlier.

Analysts surveyed by Capital IQ expected $106.6 million.

The company said it now expects $435 million to $450 million in Ayvakit net product revenue in 2024, up from $390 million to $410 million anticipated previously.

Price: 109.98, Change: +1.68, Percent Change: +1.55